Delivered positive Phase 1b clinical data in liver cirrhosis, with results presented at EASL 2025
Completed a randomised Phase 2a clinical trial (n=122) in IBS, demonstrating positive safety and efficacy signals across both IBS-C and IBS-D cohorts. Topline IBS-C data were presented as a late-breaking oral presentation at DDW 2025
Progressing an investigator-initiated Phase 2 study in allogeneic haematopoietic stem cell transplantation (allo-HSCT) patients in collaboration with Imperial College London
Across clinical studies to date, EBX-102-02 has demonstrated a favourable safety and tolerability profile

Clinical pipeline